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• 3-Fucosyl-N-acetyl-lactosamine is trisaccha- 
ride designated as CD15. Its most salient property is 
self recognition, which is seldom found in nature. 
Based on its transient feature in brain tissue and its 
differential expression during aging several func- 
tions have been proposed for this sugar. The most 
acceptable is still regulation of adhesion during 
development and aging. Sugar expression evolves 
from the production of the enzymes involved in the 
synthesis of the sugar. Therefore research has been 
directed fawards the CD 15 constituting enzymes al- 
pha 3-fucosyltransferases and their chromosomal 
localization. Since CD 15 can be used in typing tu- 
mors, it's use in pathological research has increased 
in recent years. 
INTRODUCTION 
• CD15 (Fig. 1) is known by a series of trivial 
names: lacto-N-fucopentaose II (LFPII), X, Lewis x 
(Le
x
), fucose-N-acetyl-lactosamine (FAL) and as a 
component of Stage Specific Embryonic Antigen-1 
(SSEA-1). The various names reflect the history of 
the discovery of CD 15. The milk oligosaccharides 
lacto-N-fucopentaose I and II were first isolated and 
characterized in the 1950's. These sugars were soon 
related to blood group: lacto-N-fucopentaose II as 
Le
a
 using haemaglutination inhibition assays. Le
a 
was initially termed X, but later on replaced by Le
x 
(Lewis x) to overcome confusion with antigens related 
to the x chromosomes (1). 
The term Stage Specific Embryonic Antigen was 
introduced by the Feizi group (2) as a consequence 
of their study of antigens important during mouse 
embryogenesis. They detected that SSEA antigens 
contained alpha 1-3 fucosylated types (3). Once it 
was established that N-acetyl lactosamine was in- 
volved, the term FAL was introduced and later on 
CD15. 
The study of CD 15 was intensified after the demon- 
stration of this sugar as a myeloid associated antigen 
and its localization on various granulocyte-mem- 
brane glycoproteins involved in cancer and inflam- 
mation (4). In the 80's a series of antibodies were 
reported that detected 3 alpha-fucosyl-N-acetyl 
lactosamine. At the First International Workshop on 
Human Leucocyte Differentiation Antigens held in 




identical reaction pattern (e.g. B4.3, VIM D5, 
FMC10, FMC12 and FMC13) (5). The fifth work- 
shop expended the amount of antibodies that de- 
tected CD 15 (see Table 1). The establishment of an 
unifying nomenclature in conjunction with the speci- 
fication of the pertinent antibodies detecting CD 15 
contributed to an increase in quality of the papers 
involved. 
BIOCHEMISTRY OF CD15 
• The immunodominant structure is a trisaccha- 
ride cosisting of a N-acetyl-lactosamine (Gal betal- 
4GlcNAc) unit with a fucose (Fuc) residue attached 
  
Table 1. Results of the CD15 cluster workshop of the fifth international workshop on leucocyte antigens* 
 
* Organs tested for CD15 positivity are gut, bladder, breast, lung parenchyma, lymph node, pancreas, ovary, 
peritoneum, mesenchymal soft tissues, adrenal cortex, adrenal medulla, and testes. The three tissues most 





4GlcNAc) unit with a fucose (Fuc) residue attached 
to it in the alpha 1-3-linkage (6). This sugar can be 
linked to O- and N-glycoproteins and to glycolipids. 
The sialylated form and the non-sialylated form is 
found throughout the human body and in other 
organisms. Cell surface expression of both CD 15 
and sialyl-CD 15 is developmentally regulated and is 
tumor-associated. The synthesis starts with LAG 
(Fig. 2), which is the synthesis of repeats of 
GlcNAcbeta-1-3 and Galbetal-4. This substance 
can be either alphaS-sialylated producing 3'-sialyl- 
LAG or alpha3-fucosylated which may yield the 
CD15 structure. 3'-Sialyl-LAG can be alpha-3 
fucosylated to sialyl CD 15 (7). In the biosynthesis of 
the alpha3-sialylated structures sialylation has to 
precede fucosylation, because none of the known 
sialyltransferases to date is capable of acting on 
fucosylated substances (8). The action of the alphaS- 
fucosyltransferases appears to be the critical step in 
the synthesis of these determinants and therefore the 
regulation of expression of the genes coding for 
these enzymes is expected to play an important role 
in the expression of malignant phenotypes and in the 
control of cell adhesion events. In general three 
 
Figure 2. Metabolic pathways leading to CD 15 andsialyl CD15. 
Abbreviations used are: 
(X3-FT: (x3-fucosyltransferase 
G:Galpl-^4  . 
GN: GlcNAcpl->3 
F: Fuca—>3 
LAG: repeats ofGalpl->4GlcNAcpl-+ 
SA:NeuAca2-*3 
O3-SAT: a-sialyltransferase * 
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different alphaS-fucosyl transferases can be distin- 
guished by criteria such as pH optimum, Km values, 
cation requirements and sensitivity to inhibitors. 
The main difference is in their acceptor specificity 
(9). These enzymes all are capable of transfering 
fucose from the donor substrate GDP-fucose to a 
beta 4-galacto-sylated GLcNAc residue in the N- 
acetyl-lactosamine type acceptor structures. It is in 
the specificity for additional structural features of 
acceptor molecules that alphaS-fucosyltransferases 
differ. The plasma type alphaS-fucosyltransferase 
and the Lewis type alpha 3/4-fucosyltransferase are 
both capable of functioning using sialylated sugars. 
The myeloid-type alphaS-fucosyltransferase cannot 
and it is this type that is predominantly present in 
nervous tissue (7). 
CHROMOSOMAL LOCALIZATION OF ALPHAS- 
FUCOSYLTRAMSFERASES 
• The gene coding for the plasma-type alphaS- 
fucosyltransferase is syntenic, homologous but non- 
allelic to the Lewis locus on human chromosome 19 
(10). The Lewis-type alphaS-fucosyltransferaseis a 
product of the human Lewis blood group locus, 
which is localized on chromosome 19 (11). Of all 
individuals in the European population less than 
10% are Lewis (CD 15) negative, and these persons 
do not express the Lewis fucosyltransferase (9). 
The myeloid-type alphaS-fucosyltransferase has 
been located on chromosome 11 by somatic hybrid- 
ization (12). Despite the defferential chromosome 
localization of the cDNA this enzyme shows a 
considerable similarity to that of the plasma type 
and the Lewis type enzymes. It has therefore been 
suggested that the genes of these enzymes all belong 
to an evolutionarily related family (10). 
CELL ADHESIOM PROPERTIES OF CD15 
• Several sugars only slightly deviating from 
the structure of CD 15 exist. Le
y
 has been the new 
name of Le
b
 and differs from CD 15 (Le
x
) in that an 
extra fucosylation (Fuc-alpha 1-2) is present. The H 
sugar is the Le
y
 without the alphal-3 fucolysation. 
The interaction between various fucosy ated 
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(Fig. 3). Certain sugars will recognize themselves 
and in this respect are seldom found in nature. 
Sugars that contain receptor and ligand properties in 
itself are CD 15 and H. Other sugars among them 
produce weak bonding (eg H-CD15). Sialylated 
CD 15 is recently identified as target molecule for E- 
selectin (ELAM-1), linking this sugar to selectin- 
dependent leucocyte processes and therefore to in- 
flammation. CD 15 is expressed during platelet acti- 
vation (13). CD 15 functions as an adhesion mol- 
ecule capable of Ca
2+
 mediated homotypic binding. 
Cells with high surface expression of CD 15 there- 
fore exhibit strong self-aggregation (based on CD 15- 




• Glycolipids bearing the CD 15, dimeric CD 15 
and even trimeric CD 15 determinants are tumor 
associated. All the CD 15 and CD 15 related sub- 
stances were named tumor-associated carbohydrate 
antigen (TAGA) (14). This includes sialosyl-CD15. 
The human cancers involved include colonic, lung, 
bladder, neural and gastric carcinoma. Bladder can- 
cer in humans expresses CDlS-related carbohy- 
drate epitopes. Sialyl-CD15 possibly interacts with 
 
Figure 3. Interactions of various CD15 related 
antigens: CD15-to-CD15 and H-to-H interac- 









selectin, while bound to a 60 kD glycoprotein (15). 
Expression of CD 15 in tumors of the nervous system 
occurs too (16). CD15 was seldom reported in low 
grade gliomas, but present in metastatic carcino- 
mas, meningiomas, germinomas and malignant 
melanomas. The same study also used rat glioma 
cell lines. In these rat cell lines CD 15 expression is 
absent. Myeloid leukaemia cells express CD 15 in a 
heterogeneous manner. 
AI\ITIBODIESTOCD15  
H Several monoclonal antibodies exist, that are 
claimed to demonstrate the presence of CD 15. Com- 
plicating the study of CD 15 is the fact that CD 15 
may be sialylated at the terminal position in which 
case only neuraminergic treatment will reveal the 
CD 15 residue. Mostmurine monoclonal antibodies 
to CD 15 are IgM and do not react whith sialylated 
CD 15. In the workshop on CD 15 from the fifth 
international workshop on leucocyte antigens four 
out of twenty-five of the tested monoclonal antibod- 
ies positive for CD 15 were IgG(17) (Table 1). 
CD15 ll\l THE HERVOUS SYSTEM 
• CD 15 is a good determinant in the study of 
aging of the brain. Age related expression patterns 
are demonstrated for the human lateral geniculate 
nucleus (18), but also for the monkey lateral 
geniculate body over years (19). The increase in 
expression of the CD 15 epitope in the human nucleus 
basalis of Meynert could be related to a network 
density change of astrocytes in the lateral part of the 
same nucleus in cases of Huntington's disease. In 
organic brain diseases and other psychiatric disor- 
ders changes in CD 15 expression could not be 
correlated to the specific diseases (20). 
CDlSisasugar whose expression in central nervous 
structures varies during the course of development. 
In the developing rat spinal cord CD 15 is restricted 
to alar plate and the dorsal root entrance zone. A 
transitional stage expression of CD 15 in this case is 
present, ending up with a mature expression in 
lamina II of Rexed. Although the dorsal root en- 
trance zone is positive for CD 15, no CD 15 positivity 
could be found in the dorsal root ganglion cells (21), 
indicating a heterogenous expression of CD 15 over 
subunits of neural structure. 
Differential expression of CD 15 was also studied in 
the vertebrate cerebellar cortex. CD 15 was positive 
in glial cells and neuronal structures. In rodents, the 
monkey and man the CD 15 positivity could be 
attributed to cerebellar Bergmann fibers of the Golgi cell. 
A typical topographic distribution in parasagittal bands 
was demonstrated in the mouse cerebellum and the devel- 
oping human cerebellar cortex (22). 
In the development of the rat, CD 15 is not expressed 
in dorsal root ganglion cells. The contrary is true for 
the expression of CD 15 in a subset of dorsal root 
ganglion cells during chick embryonic development 
(23), indicating species variability in the expression 
of CD15 (see also 22). 
In the adult guinea pig inner ear, CD 15 was demon- 
strated in the tectorial membrane of the cochlea and 
the endolymphatic sac. The upper part of the main 
body of the tectorial membrane stained abundantly, 
while in the rugosal and distal part of the endolym- 
phatic sac several unequally distributed cells showed 
strong intra- and extraceilularpresence of this epitope 
(24). 
Figure 4 shows CD15-positive areas in the cat brain. 
CD15 AMD CULTURED NEURAL CELLS 
H Astrocytes in culture will express CD 15 (25). 
20% of immortalized astrocytes derived from em- 
bryonic rat brain (El9/20) will express CD 15 lo- 
cated at specific morphological features. In the 
presence of retinoic acid the proportion of CD 15- 
positive astrocytes increased in a time dependent 
manner, reaching about 90% within four days, again 
related to typical morphological features like 
perinuclear granula, tips of astrocyte processes and 
contract sites between astrocytes. After treatment 
with neuraminidase all astrocytes showed CD 15 
positivity, revealing the epitope partially masked by 
sialylation (25). 
The expression of CD 15 in dissociated cultured rat 
dorsal root ganglia was studied in five experimental 
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Figure 4. Half sections stained for CD15 (LeuMl) though cortex, hippocampus and mesencephalon (a) ami 
though the frontal cortex (b). Note the differential staining in cortex, the strong poditivity for CD15 in the 
hippocampus and absence ofCDlSpositivity in the mesencephalon (cat brain fixated in 4% formaldehyde, 









situations: chemically defined medium and the same 
medium with added nerve growth factor, retinoic 
acid or antibodies against insulin or tyrosine phos- 
phate. Using astrocyte cultures as a positive control 
for exclusion of newly developed monoclonal anti- 
bodies that did not react with CD 15, it was shown 
that masking of the CD 15 antibody occurs, which 
influence the detection capacity of the monoclonal 
antibodies used. Moreover, in contrast to the vivo 
situation, two populations of dorsal root ganglion 
cells could be discerned: a CDlS-positive and a 
CD 15-negative population. The CD 15 expression is 
not involved in the outgrowth of protrusions or the 
ensheathing by non-neuronal cells of dorsal root 
ganglion cells (26). 
CD15 AMD MEUTROPHILS 
H Polymorphonuclear neutrophils play an im- 
portant role in the defence against invading patho- 
gens. Neutrophils are also the major cells of the 
acute inflammatory response. They also express 
CD 15 antigens. CD 15 antibodies affect a series of 
neutrophil functions including adhesion to endothe- 
lium, phagocytosis, stimulation of degranulation 
and the respiratory burst (27). The addition of low 
concentration of antibodies to CD 15 to neutrophils 
enhances the adherence of neutrophils to substrates, 
possibly mediated by selectins. It therefore seems 
possible that CD 15 plays a role in the activation of 
integrin-dependent adhesion. 
THE FUNCTION OF CD15 
The function of CD 15 is not well characterized and 
is most likely multifactorial. 
•       Brain 
Till now several functions were proposed for the 
CD 15 antigen in the brain. However its function in 
the brain will be different from that in the periphery. 
Within the brain, adhesion is expected to be the main 
function of CD 15, being both receptor and ligand. 
Transient expression could be an argument in favour 
of this function. Since the neural turnover of astro- 
cytes and the morphology of neurons is changing 
during aging and CD 15 patterns are not constant 
either during the same process, a continuously shift- 
ing adhesion situation during aging is to be ex- 
pected. 
      Neutrophils 
In neutrophils, CD 15 clearly seems to contribute to 
their adhesion to substrates enhancing their function 
in defence against pathogenic organisms and in the 
inflammatory response. 
       Tumors 
The function of CD 15 in tumors is presumably 
related to the dedifferentiating process. 
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